ACTION
Inhibition of PAF (platelet activating factor), Antioxidant (free-radical scavenging), Reduction of blood viscosity (causes an increase in the rate of blood flow), Neuro-protection, Stabilization of capillary permeability.
INDICATIONS
Ginkgo biloba is a plant extract used to alleviate symptoms associated with cognitive deficits, e.g., decreased memory performance, lack of concentration, decreased alertness, tinnitus, and dizziness. A treatment period of 4 to 6 weeks is needed before a pronounced effect could be expected (Soholm, B. 1998).
In hypersensitive individuals, cells of the polymorphonuclear (PMN) leukocyte family (basophils, neutrophils and eosinophils) macrophages, and monocytes are coated with IgE molecules that are specific for a particular antigen (e.g., pollen, dust, insect stings, certain molecules in foods). Subsequent re-exposure to the antigen and formation of antigen-IgE complexes provokes the synthesis and release of PAF. PAF is not stored in the body but only synthesized and released when PMNs are stimulated.
When PAF is released, they cause; platelet aggregation, edema, PMN cell chemotaxis, contraction of smooth muscle, reduction of coronary circulation, hypertension, bronchoconstriction, increase permeability of cutaneous vessels, raised haematocrit, and secretion of lysosomal enzymes.
Ginkgolide B blocks the binding of PAF to membrane receptors (Simon, M.F. et al., 1987) .
Platelet activating factor (PAF)
GINKGOLIDE
R1
R2
R3
R4
Ginkgolide A
H
HO
H
HO
Ginkgolide B
H
HO
HO
HO
Ginkgolide C
HO
HO
HO
HO
Ginkgolide J
HO
HO
H
HO
Ginkgolide M
HO
H
HO
HO
KEY CONSTITUENTS
Terpenoids (bilobalide), Diterpenoids (ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, ginkgolide M), Flavonoids: Flavones(luteolin, tricetin, 2-hydroxyluteolin), Biflavones (amentoflavone, ginkgetin, isoginkgetin, sciadoptysin, 5-methoxybilobetin, bilobetin), Flavonols (caempherol, quercetin, isorhammetin), Flavone glycosides, Flavone acyl glycosides, Catechins, Steroids (sitosterol, sitosterol glucoside).
REFERENCES
Ernst, E. and Matrai, A. (1986). Hamorheologische in-vitro Effekte von Ginkgo biloba. Herz/Kreislauf. 18;358.
Pincemail, J., Thirion, A., Dupuis, M., Braquet, P., Drieu, K., and Delby, C. (1987). Ginkgo biloba Extract Inhibits Oxygen Species Production Generated by Phorbol Myristate Acetate Stimulated Human Leukocytes. Experientia. 43(2); 181-184.
Pincemail, J., Dupuis, M., Nasr, C., Hans, P., Haag-Berrurier, M., Anton, R. and Delby, C. (1989). Superoxide Anion Scavenging Effect and Superoxide Dismutase Activity of Ginkgo biloba Extract. Experientia. 45(8); 708-712.
Pincemail, J. and Deby, C. (1991). In: F.H. Kemper and H. Schmid-Schonbein, eds. Ginkgo biloba EGb 761, Vol.1; Pharmakologie, pp.91-102. Springer Verlag, Berlin.
Simon, M.F., Chap, H., Braquet, P. and Douste-Blazy, L. (1987). Effect of BN 52021, a specific Antagonist of Platelet Factor (PAF-acether), on Calcium Movements and Phosphatidic Acid Production Induced by PAF-acether in Human Platelets. Thromb. Res. 45(4);299-309.
Soholm, B. (1998). Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. Adv. Ther. 15(1):54-65.
| These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. |